Bellicum Pharmaceuticals, Inc. – NASDAQ:BLCM
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Bellicum Pharmaceuticals stock price monthly change
-20.00%
month
Bellicum Pharmaceuticals stock price quarterly change
-4.38%
quarter
Bellicum Pharmaceuticals stock price yearly change
-92.32%
year
Bellicum Pharmaceuticals key metrics
Market Cap | 778.32K |
Enterprise value | N/A |
P/E | -0.38 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 1.66 |
Price/Book | 0.82 |
PEG ratio | N/A |
EPS | -1.58 |
Revenue | N/A |
EBITDA | -25.33M |
Income | -21.79M |
Revenue Q/Q | N/A |
Revenue Y/Y | 0.53% |
Profit margin | -1157.06% |
Oper. margin | -1248.43% |
Gross margin | 0% |
EBIT margin | -1248.43% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBellicum Pharmaceuticals stock price history
Bellicum Pharmaceuticals stock forecast
Bellicum Pharmaceuticals financial statements
| Dec 2022 | 500K | -6.19M | -1239% |
|---|---|---|---|
| Mar 2023 | 8K | -7.48M | -93587.5% |
| Jun 2023 | 0 | -7.35M | |
| Sep 2023 | 1M | -763K | -76.3% |
| 2025 | 6M | -15.41M | -256.9% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-05-11 | -0.19882 | -0.26 |
|---|
| Dec 2022 | 23823000 | 21.80M | 91.54% |
|---|---|---|---|
| Mar 2023 | 17260000 | 27.28M | 158.05% |
| Jun 2023 | 8733000 | 30.57M | 350.09% |
| Sep 2023 | 6853000 | 33.86M | 494.19% |
| Dec 2022 | -6.91M | -7K | 0 |
|---|---|---|---|
| Mar 2023 | -6.43M | -5K | 0 |
| Jun 2023 | -7.99M | 1K | 0 |
| Sep 2023 | -1.51M | 15K | 0 |
Bellicum Pharmaceuticals alternative data
| Aug 2023 | 13 |
|---|---|
| Sep 2023 | 13 |
| Oct 2023 | 13 |
| Nov 2023 | 13 |
| Dec 2023 | 13 |
| Jan 2024 | 13 |
| Feb 2024 | 13 |
| Mar 2024 | 13 |
| Apr 2024 | 13 |
| May 2024 | 13 |
| Jun 2024 | 13 |
| Jul 2024 | 13 |
Bellicum Pharmaceuticals other data
15.10%
+0.70%
of BLCM is owned by hedge funds
1.73M
+269.16K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2019 | 28000 | 0 |
| Sep 2019 | 40000 | 0 |
| Mar 2020 | 5000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | STONEHOUSE JON P director | Common Stock | 121,452 | N/A | N/A | ||
Option | HUBER REID M director | Common Stock | 87,196 | N/A | N/A | ||
Option | DAVIS STEPHEN director | Common Stock | 74,739 | N/A | N/A | ||
Option | DALY JAMES M director | Common Stock | 60,414 | N/A | N/A | ||
Option | KLIMOVSKY JUDITH V director | Common Stock | 60,414 | N/A | N/A | ||
Option | HUBER REID M director | Common Stock | 80,968 | N/A | N/A | ||
Option | STONEHOUSE JON P director | Common Stock | 60,580 | N/A | N/A | ||
Option | HUBER REID M director | Common Stock | 46,489 | N/A | N/A | ||
Option | DALY JAMES M director | Common Stock | 35,082 | N/A | N/A | ||
Option | STONEHOUSE JON P director | Common Stock | 60,580 | N/A | N/A |
| Patent |
|---|
Application Filling date: 12 Aug 2020 Issue date: 1 Sep 2022 |
Application Filling date: 21 Jun 2021 Issue date: 19 May 2022 |
Application Filling date: 9 Jun 2021 Issue date: 28 Apr 2022 |
Application Filling date: 12 Dec 2019 Issue date: 3 Mar 2022 |
Application Filling date: 29 Oct 2019 Issue date: 6 Jan 2022 |
Application Filling date: 7 Dec 2020 Issue date: 11 Nov 2021 |
Application Filling date: 8 May 2018 Issue date: 20 May 2021 |
Application Filling date: 6 May 2019 Issue date: 15 Apr 2021 |
Grant Utility: Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 Filling date: 13 Feb 2015 Issue date: 2 Mar 2021 |
Grant Filling date: 11 Feb 2020 Issue date: 16 Feb 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2020 30 Mar 2021 | Q4 2020 Earnings Call Transcript |
| Q2 2020 7 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Q4 2019 13 Mar 2020 | Q4 2019 Earnings Call Transcript |
| Q3 2019 7 Nov 2019 | Q3 2019 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Richard A. Fair (1969) Pres, Chief Executive Officer & Director | $896,530 |
Thursday, 16 March 2023 | ||
| Bellicum (BLCM) Down on Ending Development of CAR-T Candidates | Zacks Investment Research | |
Monday, 27 February 2023 | ||
| Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year? | Zacks Investment Research | |
Thursday, 19 January 2023 | ||
| Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium | GlobeNewsWire | |
Thursday, 1 September 2022 | ||
| Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference | GlobeNewsWire | |
Friday, 3 September 2021 | ||
| Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference | GlobeNewsWire | |
Wednesday, 1 September 2021 | ||
| BLCM Stock: Over 12% Increase Pre-Market Explanation | Pulse2 | |
| Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch | GlobeNewsWire |
-
When is Bellicum Pharmaceuticals's next earnings date?
Unfortunately, Bellicum Pharmaceuticals's (BLCM) next earnings date is currently unknown.
-
Does Bellicum Pharmaceuticals pay dividends?
No, Bellicum Pharmaceuticals does not pay dividends.
-
How much money does Bellicum Pharmaceuticals make?
Bellicum Pharmaceuticals has a market capitalization of 778.32K and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 75.81% to 1.5M US dollars. Bellicum Pharmaceuticals made a loss 24.97M US dollars in net income (profit) last year or -$0.26 on an earnings per share basis.
-
What is Bellicum Pharmaceuticals's stock symbol?
Bellicum Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "BLCM".
-
What is Bellicum Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Bellicum Pharmaceuticals?
Shares of Bellicum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Bellicum Pharmaceuticals's key executives?
Bellicum Pharmaceuticals's management team includes the following people:
- Mr. Richard A. Fair Pres, Chief Executive Officer & Director(age: 56, pay: $896,530)
-
How many employees does Bellicum Pharmaceuticals have?
As Jul 2024, Bellicum Pharmaceuticals employs 13 workers.
-
When Bellicum Pharmaceuticals went public?
Bellicum Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 18 Dec 2014.
-
What is Bellicum Pharmaceuticals's official website?
The official website for Bellicum Pharmaceuticals is bellicum.com.
-
Where are Bellicum Pharmaceuticals's headquarters?
Bellicum Pharmaceuticals is headquartered at 3730 Kirby Drive, Houston, TX.
-
How can i contact Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals's mailing address is 3730 Kirby Drive, Houston, TX and company can be reached via phone at 281 454 3424.
Bellicum Pharmaceuticals company profile:
Bellicum Pharmaceuticals, Inc.
bellicum.comExchange:
NASDAQ
Full time employees:
13
Industry:
Biotechnology
Sector:
Healthcare
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
3730 Kirby Drive
Houston, TX 77098
Houston, TX 77098
CIK: 0001358403
ISIN: US0794814048
CUSIP: 079481404
